Literature DB >> 20546289

Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions.

L Pala1, S Ciani, I Dicembrini, G Bardini, B Cresci, A Pezzatini, S Giannini, E Mannucci, C M Rotella.   

Abstract

AIM: The reduced levels of glucagon-like peptide 1 (GLP-1) after an oral glucose load in Type 2 diabetic patients could be dependent either on a reduced synthesis or an increased degradation; but GLP-1 and dipeptidyl peptidase IV (DPP-IV) levels during an oral glucose tolerance test (OGTT) have not been studied together. The aim of the present study was to investigate GLP-1 and DPP-IV levels during an OGTT in patients with different degrees of glucose tolerance.
METHODS: Fifty six subjects (34 female, 22 male) matched for sex, age, body mass index (BMI) and waist circumference underwent a 75 g oral glucose tolerance test. Twenty-eight had normal glucose tolerance, 15 had impaired glucose tolerance and 13 had Type 2 diabetes mellitus. GLP-1 assay was performed with an ELISA kit, and DPP-IV assay using a colorimetric method.
RESULTS: At 30 min GLP-1 levels were significantly lower in subjects with impaired glucose tolerance and type 2 diabetes mellitus compared to those with normal glucose tolerance. The area under the GLP-1 curve was significantly different among the three groups; there was a significant decrease between subjects with normal and impaired glucose tolerance(P = 0.004) and between those with normal glucose tolerance and type 2 diabetes mellitus. (P < 0.001), while the area under the curve for DPP-IV showed no significant difference between the groups.
CONCLUSIONS: These results suggest that an increase of GLP-1 degradation does not play a role in the early stages of diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20546289     DOI: 10.1111/j.1464-5491.2010.03010.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  17 in total

1.  Defects in GLP-1 response to an oral challenge do not play a significant role in the pathogenesis of prediabetes.

Authors:  Galina Smushkin; Airani Sathananthan; Chiara Dalla Man; Alan R Zinsmeister; Michael Camilleri; Claudio Cobelli; Robert A Rizza; Adrian Vella
Journal:  J Clin Endocrinol Metab       Date:  2011-11-16       Impact factor: 5.958

2.  Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways.

Authors:  Zubair Shah; Colleen Pineda; Thomas Kampfrath; Andrei Maiseyeu; Zhekang Ying; Ira Racoma; Jeffrey Deiuliis; Xiaohua Xu; Qinghua Sun; Susan Moffatt-Bruce; Frederick Villamena; Sanjay Rajagopalan
Journal:  Vascul Pharmacol       Date:  2011-03-10       Impact factor: 5.773

3.  Emetic Response to T-2 Toxin Correspond to Secretion of Glucagon-like Peptide-17-36 Amide and Glucose-Dependent Insulinotropic Polypeptide.

Authors:  Jie Zhang; Tushuai Li; Qinghua Wu; Zihui Qin; Ben Wei; Ran Wu; Xinyi Guo; Huiping Xiao; Wenda Wu
Journal:  Toxins (Basel)       Date:  2022-06-02       Impact factor: 5.075

Review 4.  Diabetic gastroparesis: functional/morphologic background, diagnosis, and treatment options.

Authors:  Viktor J Horváth; Ferenc Izbéki; Csaba Lengyel; Péter Kempler; Tamás Várkonyi
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

5.  High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV.

Authors:  C Marchetti; A Di Carlo; F Facchiano; C Senatore; R De Cristofaro; A Luzi; M Federici; M Romani; M Napolitano; M C Capogrossi; A Germani
Journal:  Diabetologia       Date:  2011-06-08       Impact factor: 10.122

Review 6.  Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function.

Authors:  Chinmay S Marathe; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Exp Diabetes Res       Date:  2011-06-22

Review 7.  From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.

Authors:  Ilaria Dicembrini; Laura Pala; Carlo Maria Rotella
Journal:  Exp Diabetes Res       Date:  2011-06-23

8.  Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian Subjects.

Authors:  Radwan H Ahmed; Hasniza Zaman Huri; Zaid Al-Hamodi; Sameer D Salem; Sekaran Muniandy
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

9.  Regulation of dipeptidyl peptidase 4 production in adipocytes by glucose.

Authors:  Siddhartha Shankar Das; Hiroto Hayashi; Taiki Sato; Ren Yamada; Masahiro Hiratsuka; Noriyasu Hirasawa
Journal:  Diabetes Metab Syndr Obes       Date:  2014-05-24       Impact factor: 3.168

Review 10.  Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions.

Authors:  Awadhesh Kumar Singh
Journal:  Indian J Endocrinol Metab       Date:  2014-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.